The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the leading authority on illicit drugs in the European Union, with the main objective to provide independent scientific evidence and analysis on all aspects of this constantly changing threat to individual lives and wider society.
As such, the work of the Centre has always been informed by the research findings conducted at national, European and international levels, and guided by the EMCDDA's Scientific Committee (composed of 15 well-known EU national scientists). Over the years, the EMCDDA has been innovating in the drugs field by strengthening methods, tools and analytical approaches and ensuring their dissemination to relevant stakeholders.
The new Regulation establishing the European Union Drugs Agency (EUDA), which enters into application on 2 July 2024, provides new competencies in the areas of research and innovation.
The new mandate tasks the agency to:
- support the European Commission and the EU Member States in identifying knowledge gaps and research priorities in the drugs area;
- conduct and commission studies to address critical knowledge gaps or follow up on potential health and security threats; and
- identify, utilise and encourage the adoption of innovation in areas relevant to the agency's mandate.
The new competencies will allow the agency to keep pace with an increasingly complex and rapidly changing drug phenomenon, fuelled by globalisation and technological developments.
In the security area, this will intensify the EUDA's contribution to: the EU Innovation Hub for internal security; the development of forensic and toxicological capabilities to identify novel substances and multiple substances in biological samples; and the building of threat assessment and rapid alert systems in the drugs field.
The agency will also promote synergies and foster cooperation and networking among European researchers and innovation projects.
- Publication date
- 6 October 2023
- Directorate-General for Migration and Home Affairs